Add Company
Join Now

POINT Biopharma Revenue and Competitors

License our Company Data API

Toronto, ON CAN

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • POINT Biopharma's estimated annual revenue is currently $38.6M per year.(i)
  • POINT Biopharma's estimated revenue per employee is $155,000

Employee Data

  • POINT Biopharma has 249 Employees.(i)
  • POINT Biopharma grew their employee count by 40% last year.

POINT Biopharma's People

NameTitleEmail/Phone
1
EVP Regulatory AffairsReveal Email/Phone
2
VP, Discovery and Translational SciencesReveal Email/Phone
3
EVP Regulatory AffairsReveal Email/Phone
4
QC AnalystReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.2M2729%$5MN/A
#2
$1.7M1122%N/AN/A
#3
$0.9M11-72%$39.4MN/A
#4
$1M13-84%$23.8MN/A
#5
$94.4M6098%N/AN/A
#6
$3.4M2210%N/AN/A
#7
$9.5M61-68%N/AN/A
#8
$18.1M11730%N/AN/A
#9
$21.7M140-6%N/AN/A
#10
$1M13-41%N/AN/A
Add Company

What Is POINT Biopharma?

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

keywords:N/A

N/A

Total Funding

249

Number of Employees

$38.6M

Revenue (est)

40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

POINT Biopharma News

2022-04-20 - First European Union Patient Dosed with 177Lu-PNT2002 in ...

POINT Biopharma's Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US,...

2022-04-06 - POINT Biopharma to Present on its Pan-Cancer FAP-Alpha ...

INDIANAPOLIS, April 11, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”),...

2022-03-22 - PLUVICTO's approval mounts pressure on POINT ...

PLUVICTO's FDA approval extends pressure on POINT Biopharma's rival targeted radioligand therapy, PSMA [Lu-177]-PNT2002, whose estimated...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M2498%N/A
#2
$74M24911%N/A
#3
$45.2M249N/AN/A
#4
$41.1M249-2%N/A
#5
$41.3M250N/AN/A